Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia
Public ClinicalTrials.gov record NCT05110157. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects With Schizophrenia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.
Study identification
- NCT ID
- NCT05110157
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 442 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 29, 2021 (Actual)
- Primary completion
- Feb 4, 2025 (Actual)
- Completion
- Feb 18, 2025 (Actual)
- Last update posted
- Feb 10, 2026
2021 – 2025
United States locations
- U.S. sites
- 50
- U.S. states
- 15
- U.S. cities
- 42
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Neurocrine Clinical Site | Phoenix | Arizona | 85012 | — |
| Neurocrine Clinical Site | Rogers | Arkansas | 72758 | — |
| Neurocrine Clinical Site | Anaheim | California | 92805 | — |
| Neurocrine Clinical Site | Bellflower | California | 90706 | — |
| Neurocrine Clinical Site | Culver City | California | 90230 | — |
| Neurocrine Clinical Site | Garden Grove | California | 92845 | — |
| Neurocrine Clinical Site | Lemon Grove | California | 91945 | — |
| Neurocrine Clinical Site | Long Beach | California | 90807 | — |
| Neurocrine Clinical Site | Oceanside | California | 92056 | — |
| Neurocrine Clinical Site | Pico Rivera | California | 90660 | — |
| Neurocrine Clinical Site | Riverside | California | 92506 | — |
| Neurocrine Clinical Site | San Diego | California | 92102 | — |
| Neurocrine Clinical Site | San Diego | California | 92103 | — |
| Neurocrine Clinical Site | San Jose | California | 95124 | — |
| Neurocrine Clinical Site | Santa Ana | California | 92705 | — |
| Neurocrine Clinical Site | Stanford | California | 94305 | — |
| Neurocrine Clinical Site | Torrance | California | 90502 | — |
| Neurocrine Clinical Site | Aventura | Florida | 33180 | — |
| Neurocrine Clinical Site | Coral Gables | Florida | 33134 | — |
| Neurocrine Clinical Site | Daytona Beach | Florida | 32114 | — |
| Neurocrine Clinical Site | Hialeah | Florida | 33012 | — |
| Neurocrine Clinical Site | Hialeah | Florida | 33013 | — |
| Neurocrine Clinical Site | Hialeah | Florida | 33016 | — |
| Neurocrine Clinical Site | Miami | Florida | 33133 | — |
| Neurocrine Clinical Site | Miami | Florida | 33137 | — |
| Neurocrine Clinical Site | Miami | Florida | 33144 | — |
| Neurocrine Clinical Site | Miami Lakes | Florida | 33016 | — |
| Neurocrine Clinical Site | Okeechobee | Florida | 34972 | — |
| Neurocrine Clinical Site | Tampa | Florida | 33629 | — |
| Neurocrine Clinical Site | West Palm Beach | Florida | 33407 | — |
| Neurocrine Clinical Site | Atlanta | Georgia | 30328 | — |
| Neurocrine Clinical Site | Evanston | Illinois | 60208 | — |
| Neurocrine Clinical Site | Springfield | Illinois | 62702 | — |
| Neurocrine Clinical Site | Grand Rapids | Michigan | 49503 | — |
| Neurocrine Clinical Site | St Louis | Missouri | 63125 | — |
| Neurocrine Clinical Site | St Louis | Missouri | 63128 | — |
| Neurocrine Clinical Site | Lincoln | Nebraska | 68526 | — |
| Neurocrine Clinical Site | Las Vegas | Nevada | 89102 | — |
| Neurocrine Clinical Site | Cedarhurst | New York | 11516 | — |
| Neurocrine Clinical Sites | Glen Oaks | New York | 11004 | — |
| Neurocrine Clinical Site | New York | New York | 10032 | — |
| Neurocrine Clinical Site | New York | New York | 10035 | — |
| Neurocrine Clinical Site | Charlotte | North Carolina | 28211 | — |
| Neurocrine Clinical Site | Dayton | Ohio | 45417 | — |
| Neurocrine Clinical Site | Oklahoma City | Oklahoma | 73112 | — |
| Neurocrine Clinical Site | Austin | Texas | 78754 | — |
| Neurocrine Clinical Site | Dallas | Texas | 75390 | — |
| Neurocrine Clinical Site | DeSoto | Texas | 75115 | — |
| Neurocrine Clinical Site | Houston | Texas | 77081 | — |
| Neurocrine Clinical Site | Houston | Texas | 77090 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05110157, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 10, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05110157 live on ClinicalTrials.gov.